Bradley J . Monk, MD

Department

Obstetrics & Gynecology (Phoenix)

Position

Affiliate Professor

General

• Levin Gabriel, Gilbert Lucy, Coleman Robert, Ribeiro Reitan, Monk Bradley, Gender and geographic disparity in industry payments to gynecologic oncologists in the United States 2026

Publications

• Gynecologic oncology
  Bogani Giorgio, Ferrari Filippo A., Monk Bradley J., Ray-Coquard Isabelle, Ceccaroni Marcello, Moore Kathleen N., Coleman Robert L., Fotopoulou Christina, Mabrouk Mohamed, Taylor Hugh S., Roman Horace, , Endometriosis and ovarian cancer risk
  209, p. 88 - 98 2026
• Gynecologic oncology
  Slomovitz Sadie, Eubanks Rhea, Podder Vivek, Campbell-Simms Katie, Slomovitz Brian, O'Malley David, Randall Leslie, Monk Bradley, Moore Kathleen, Eskander Ramez, Copeland Larry, Coleman Robert, Herzog Thomas, Pothuri Bhavana, Reliability of feasibility surveys for predicting patient accrual in phase III gynecologic trials
  208, p. S142 - S142 2026
• Gynecologic oncology
  Monk Bradley, Korach Jacob, Hasegawa Kosei, Kose Fatih, Zsiros Emese, Sebastianelli Alexandra, Mądry Radosław, Ibañez Carolina, Diaz Roberto Ivan Romero, Hudson Emma, , Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Final analysis results from the randomized double-blind phase 3 ENGOT-ov65/KEYNOTE-B96 study
  208, p. S31 - S31 2026
• Gynecologic oncology
  Backes Floor, Forget Frédéric, O'Malley David, Barretina-Ginesta Maria-Pilar, Monk Bradley, Willmott Lyndsay, Raaschou-Jensen Nicoline, Pisano Carmela, Follana Philippe, O'Cearbhaill Roisin, , Patient-reported outcomes from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: Results from the homologous recombination-deficient (HRd) and -p
  208, p. S25 - S26 2026
• Gynecologic oncology
  Van Gorp Toon, Oaknin Ana, denys hannelore, Ghamande Sharad, Boere Ingrid, Monk Bradley, Vergote Ignace, Randall Leslie, Tromp Jacqueline, Lorusso Domenica, Cibula David, , Tisotumab vedotin in combination with carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer: First disclosure of arm H from the ENGOT-cx8/GOG-3024/innovaTV 205 study
  208, p. S37 - S38 2026
• Gynecologic oncology
  Grisham Rachel, O'Malley David, Monk Bradley, Van Nieuwenhuysen Els, Santin Alessandro, D'Hondt Véronique, Thaker Premal, Clamp Andrew, Moore Kathleen, Aghajanian Carol, Perez-Fidalgo Alejandro, , Long-term efficacy and safety of avutometinib + defactinib in patients with recurrent low-grade serous ovarian cancer: Results from ENGOT-OV60/GOG-3052/RAMP 201
  208, p. S30 - S31 2026
• Gynecologic oncology
  Slomovitz Brian, Eskander Ramez, Starks David, Monk Bradley, Barlin Joyce, Wysham Weiya, Hester Danubia, Lee Christine, Mallen Adrianne, Anderson Charles, Jackson Amanda, Rubinstein Maria, Maddocks Oliver, Alvarez Edwin, Choksi Mamta, Crafton Sarah, DiBenedetto Samantha, Niazi Tina, Chirnomas Debbie, Sapanisertib and serabelisib (PIKTOR) with paclitaxel, and an insulin-suppressing diet (ISD) substudy, in patients with advanced/recurrent endometrial cancer (EC): GOG-3111
  208, p. S105 - S105 2026
• Gynecologic oncology
  Levin Gabriel, Monk Bradley, Ribeiro Reitan, Coleman Robert, Gilbert Lucy, From PARPis to ADCs: Changing patterns of industry payments to gynecologic oncologists
  208, p. S191 - S191 2026
• Gynecologic oncology
  Kim Jae-Weon, Yadav Bhagyashree, Pai Sachin, Slomovitz Brian, Mallen Adrianne, Lorusso Domenica, Monk Bradley, Park Jeong-Yeol, Colombo Nicoletta, Muller Carolyn, Gladieff Laurence, Olawaiye Alexander, Van Gorp Toon, Bertrán Ana Santaballa, Felberbaum Ricardo, Bodnar Lubomir, Madrid Lorena Fariñas, Thaker Premal, Pashova Hristina, BELLA: A phase 2 study of relacorilant plus nab-paclitaxel +/− bevacizumab in patients with gynecologic cancers
  208, p. S107 - S107 2026
• Gynecologic oncology
  Monk Bradley, Sánchez Luis Manso, Braicu Elena Ioana, Madry Radoslaw, Beijers Antoinetta J.M., Farolfi Alberto, Vulsteke Christof, Hasegawa Kosei, Wang Jian-Liu, Alexandre Jerome, , GOG-3119/ENGOT-en29/TroFuse-033: A phase 3, randomized study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
  208, p. S103 - S104 2026
• The Lancet (British edition)
  Lorusso Domenica, Mileshkin Linda, Quesada Stanislas, Hopp Elizabeth, Monk Bradley J, Gladieff Laurence, O'Malley David M, Kim Jae-Weon, Garbaos Gabriel, Fagotti Anna, Gilbert Lucy, , Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial
  407:10538, p. 1513 - 1524 2026
• The Lancet (British edition)
  Colombo Nicoletta, Bidzinski Mariusz, Gallardo Carlos, Matanes Emad, Hasegawa Kosei, Zsiros Emese, Parma Gabriella, Rulli Eliana, Sebastianelli Alexandra, Kose Fatih, Monk Bradley J, , Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
  407:10538, p. 1525 - 1537 2026
• Targeted therapies in oncology
  Monk Bradley, KEYNOTE-B96 Brings Immunotherapy-Based Option to Platinum-Resistant Ovarian Cancer 2026
• Gynecologic oncology
  Levin Gabriel, Coleman Robert L, Meyer Raanan, Ribeiro Reitan, Gilbert Lucy, Monk Bradley J, Industry payments to U.S. gynecologic oncologists: Gender, geographic, and therapeutic trends
  207S, p. 60 2026
• Gynecologic oncology
  Van Nieuwenhuysen Els, Vergote Ignace, Randall Leslie M, Tromp Jacqueline, Lorusso Domenica, O'Cearbhaill Roisin E, Boere Ingrid, Pisano Carmela, Sanchez Luis Manso, Banerjee Susana, Monk Bradley J, , Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study
  207S, p. 3 - 13 2026
• Banerjee Susana, Clamp Andrew, Van Nieuwenhuysen Els, Aghajanian Carol, D'Hondt Veronique, Monk Bradley, Oaknin ANA, The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201 2026
• International journal of gynecological cancer
  Denschlag Dominik, Cloven Noelle, Pennington Kathryn, Monk Bradley J., Powell Matthew A., Roed Henrik, Gilbert Lucy, Zub Oleksandr, Mccourt Carolyn, Fleming Evelyn, Angioli Roberto, , Post-hoc survival outcomes based on initial and subsequent treatment in patients with mmrp/MSS primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
  36:2, p. 104434 2026
• International journal of gynecological cancer
  Konstantinopoulos Panagiotis, Song Mihae, Eskander Ramez N., Matei Daniela, Winer Ira, Bradley William H., Brubaker Lindsay W., Guy Michael, Mcnamara Donna, Turner Rachael, Monk Bradley J., , CLINICAL ACTIVITY OF ACR-368 IN PATIENTS WITH ENDOMETRIAL CARCINOMA PROSPECTIVLY SELECTED BY ONCOSIGNATURE – A PHASE 2 STUDY - ACR-368-201/GOG3082 (NCT05548296)
  36:2, p. 104573 2026
• International journal of gynecological cancer
  González-Martín Antonio, O'Malley David M., Galaz Cristina Churruca, Vulsteke Christof, Chase Dana M., Koliadi Anthoula, Braly Patricia, Lorusso Domenica, Chan John K., D'Hondt Véronique, Willmott Lyndsay J., Monk Bradley J., , Predictors of long-term progression-free survival in patients treated with niraparib first-line maintenance therapy in the phase 3 randomised placebo-controlled PRIMA/ENGOT-OV16/GOG-3012 trial
  36:2, p. 103081 2026
• International journal of gynecological cancer
  Zagouri Flora, Diaz John Paul, Zeng Xing, Prado Purificación Martinez- Del, Jewell Andrea, Salutari Vanda, Van Le Linda, Lu Chien-Hsing, Kuru Oguzhan, Bradford Leslie S., Chudecka-Glaz Anita, Bradley William H., Collins Dearbhaile C., Holloway Robert, Borrow Jen, Ong Valerie, Fujiwara Keiichi, Kristeleit Rebecca S., Monk Bradley J., Rucaparib maintenance in ATHENA-MONO (GOG-3020/ENGOT-ov45) in patients with newly diagnosed advanced ovarian cancer: exploratory post-progression evaluations for patients with HRD-negative and HRD-unknown tumours
  36:2, p. 103090 2026
• International journal of gynecological cancer
  Eminowicz Gemma, Concin Nicole, Mcsorley Lynda M., Tlustý Vojtech, Zagouri Flora, Matanes Emad, Petrella Maria Cristina, Nilsen Elisabeth Berge, Fujiwara Keiichi, Wang Jian Liu, Monk Bradley J., , GOG-3119/ENGOT-en29/TROFUSE-033: A phase 3, randomised study of sacituzumab tirumotecan plus pembrolizumab vs pembrolizumab alone as first-line maintenance therapy for mismatch repair-proficient endometrial cancer
  36:2, p. 104392 2026
• JCO precision oncology
  Coleman Robert L, Willoughby David, Nagel Casey, Wei Qi, Wallraven Gladice, Horvath Staci, Rocconi Rodney, Monk Bradley J, Walter Adam, Stanbery Laura, Tang Min, Rao Donald, Bognar Ernest, Nemunaitis John, Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer
  10:10, p. e2500462 2026
• Graybill Whitney S, Vergote Ignace, Monk Bradley J, Pardo Búrdalo Beatriz, O’Malley David M, Copeland Larry J, Sabbatini Roberto, Herzog Thomas J, Follana Philippe, Auranen Annika, , Predictors of long-term progression-free survival in patients with ovarian cancer treated with niraparib in the PRIMA/ENGOT-OV26/GOG-3012 study 2025
• Future oncology (London, England)
  Banerjee Susana N, Van Nieuwenhuysen Els, Aghajanian Carol, Monk Bradley J, Clamp Andrew, D'Hondt Véronique, Rodrigues Manuel, Chon Hye Sook, Prendergast Emily, Oaknin Ana, Ring Kari, Holloway Robert W, Colombo Nicoletta, Gennigens Christine, Newman Gregg, Salinas Erin, Youssoufian Hagop, Santin Alessandro D, O'Malley David M, Gourley Charlie, Thaker Premal H, Moore Kathleen N, Lustgarten Stephanie, Van Gorp Toon, Grisham Rachel N, The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201, p. 1 2025
• Moore Kathleen, Fabbro MICHEL, OMalley David, Grisham Rachel, Monk Bradley, Van Nieuwenhuysen Els, GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer 2025
• International journal of gynecological cancer
  Eskander Ramez N., Slomovitz Brian, Makker Vicky, Moore Kathleen N., Monk Bradley, Gonzalez-Martin Antonio, Fujiwara Keiichi, Oza Amit, Oaknin Ana, Leary Alexandra, Sehouli Jalid, Rider Alex, Brown Tom, Ali Talal, Smith Alan, Gourley Charlie, REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED PLATINUM-RESISTANT AND PLATINUM-SENSITIVE OVARIAN CANCER WITHIN THE UNITED STATES: AN ANALYSIS OF SECONDARY DATA
  35:11, p. 102488 2025
• International journal of gynecological cancer
  Hasegawa Kosei, Yañez Eduardo, Gumus Mahmut, Hurtado De Mendoza Mivael Olivera, Samouëlian Vanessa, Castonguay Vincent, Arkhipov Alexander, Tekin Cumhur, Toker Sarper, Monk Bradley, Li Kan, Tewari Krishnansu S., Dubot Coraline, Cáceres M. Valeria, Lorusso Domenica, Colombo Nicoletta, Shapira-Frommer Ronnie, Salman Pamela, PEMBROLIZUMAB PLUS CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN PARTICIPANTS WITH PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER: 5-YEAR FOLLOW-UP RESULTS FROM KEYNOTE-826
  35:11, p. 102156 2025
• International journal of gynecological cancer
  Lee Elizabeth, Call Justin, Winer Ira, Yeku Oladapo, Richardson Debra, Seamon Leigh, Hamilton Erika, Cloven Noelle, Zhang Jian, Kavalerchik Edward, Monk Bradley, PART C OF RAINFOL™-01: A PHASE 1/2 STUDY OF SINGLE-AGENT RINATABART SESUTECAN IN PATIENTS WITH ADVANCED AND/OR METASTATIC PLATINUM-RESISTANT OVARIAN CANCER
  35:11, p. 102616 2025
• International journal of gynecological cancer
  Richardson Debra, Weiner Ira, Willmott Lyndsay J., Call Justin, Pepin Jessica Thomes, Jewell Andrea, Mathews Cara, Seamon Leigh, Buscema Joseph, Monk Bradley, Guancial Elizabeth, Orr Douglas, Melnyk Anton, Gillespie Michael, Kilavuz Nurgul, Ong Teng Jin, Kavalerchik Edward, Cloven Noelle, Konecny Gottfried, Lee Elizabeth, RINATABART SESUTECAN MONOTHERAPY IN PATIENTS WITH ADVANCED ENDOMETRIAL CANCER: PART F OF THE PHASE 1/2 RAINFOL™-01 STUDY
  35:11, p. 102612 2025
• International journal of gynecological cancer
  Salani Ritu, Gilbert Lucy, Sadozye Azmat H., Do Rêgo Barros Lilian Arruda, Lee Jung-Yun, Van Gorp Toon, Boere Ingrid, Marth Christian, Mądry Radosław, Zagouri Flora, Duska Linda, Monk Bradley, Li Xin Tong, Bogusz Agata M., Toker Sarper, Lindemann Kristina, Cáceres M. Valeria, Harter Philipp, Zhongqiu Lin, Nishio Shin, Oaknin Ana, Kurtz Jean-Emmanuel, Valabrega Giorgio, Canova Stefania, TROFUSE-020/GOG-3101/ENGOT-CX20: A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL, MULTICENTER STUDY COMPARING SACITUZUMAB TIRUMOTECAN MONOTHERAPY VS TREATMENT OF PHYSICIAN’S CHOICE AS SECOND-LINE TREATMENT FOR RECURRENT/METASTATIC CERVICAL CANCER
  35:11, p. 102609 2025
• International journal of gynecological cancer
  Secord Angeles Alvarez, Sill Michael, Lankes Heather, Leitao Mario, Ramondetta Lois, Clair Kiran, Newton Meredith, Guntupalli Saketh, Richardson Debra, Disilvestro Paul, Cantuaria Guillerme, Iii Charles Leath, Billingsley Caroline, Mcdonald Megan, Liu Yingmiao, Starr Mark, Birrer Michael, Monk Bradley, Brady Chris, Lea Jayanthi, Ueland Frederick, Chambers Laura, Tewari Krishnansu S., Nixon Andrew, PREDICTIVE BLOOD-BASED BIOMARKERS IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: RESULTS FROM GOG-0240
  35:11, p. 102158 2025
• International journal of gynecological cancer
  Nicum Shibani, Zagouri Flora, Segev Yakir, Marth Christian, Collins Dearbhaile C., Kümmel Jan, Petrella Maria Cristina, Lassus Heini J., Fujiwara Keiichi, Wang Jian Liu, Lu Chien-Hsing, Monk Bradley, Jaishuen Atthapon, Cáceres M. Valeria, Freitas-Junior Ruffo, Crafton Sarah, Black Destin, Slomovitz Brian M., Orlowski Robert, Kruger Stephan, Yao Lili, GOG-3119/ENGOT-EN29/TROFUSE-033: A PHASE 3, RANDOMIZED STUDY OF SACITUZUMAB TIRUMOTECAN PLUS PEMBROLIZUMAB VS PEMBROLIZUMAB ALONE AS FIRST-LINE MAINTENANCE THERAPY FOR MISMATCH REPAIR-PROFICIENT ENDOMETRIAL CANCER
  35:11, p. 102611 2025
• International journal of gynecological cancer
  Vergote Ignace, Perez Fidalgo Jose Alejandro, Valabrega Giorgio, Monk Bradley, Herzog Thomas, Cibula David, Colombo Nicoletta, Pothuri Bhavana, Sehouli Jalid, Korach Jakob, Barlin Joyce, Papadimitriou Christos, Van Gorp Toon, Richardson Debra, Mccarthy Michael, Antill Yoland, Li Kai, Kalyanapu Pratheek, Slomovitz Brian, Coleman Robert, ENGOT-EN20/GOG-3083/XPORT-EC-042 A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA
  35:11, p. 102472 2025
• International journal of gynecological cancer
  Lorusso Domenica, Monk Bradley, Martin Lainie, Schenker Michael, Maximiano Constanza, Barlin Joyce, Kim Yong Man, Bese Tugan, Rose Peter G., Chang Chih-Long, Pospiskova Marketa, Salinas Erin A., Malander Susanne, Santin Alessandro D., Collins Dearbhaile C., Willmott Lyndsay, Craib Marcia, Chui Joshua, Fujiwara Keiichi, Kristeleit Rebecca, SAFETY OF RUCAPARIB MONOTHERAPY IN ADVANCED HIGH-GRADE OVARIAN CANCER CLINICAL TRIALS
  35:11, p. 102262 2025
• Gynecologic oncology
  Chase Dana M, Cho Chi Heum, Kim Jae-Weon, No Jae Hong, Holman Laura, Stuckey Ashley, Fabian Denise, Smick Alexandra H, Wenzel Lari, Gil Karen, Ryu Sang Young, Huang Helen Q, Deng Wei, Koh Wui-Jin, Rodgers William, Small, Jr William, Albuquerque Kevin, Mayadev Jyoti, Leath Charles A, Monk Bradley, Kim Beob-Jong, Kim Dae-Yeon, Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263)
  202, p. 102 - 109 2025
• Journal of clinical oncology
  Monk Bradley J, Coleman Robert L, O'Malley David M, Moore Kathleen N, González-Martín Antonio, Herzog Thomas J, Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer, p. JCO2501721 2025
• Molecular cancer therapeutics
  Leary Alexandra, Willmott Lyndsay, Monk Bradley J., Frenel Jean-Sébastien, Starks David C., Okera Meena, Secord Angeles Alvarez, O’Malley David M., Martin Lainie, Ouali Kaissa, Oehler Martin K., Goh Jeffrey C., Slomovitz Brian M., Lim Peter C., Shannon Catherine M., Neff Robert, Backes Floor J., Rajendran Divya, Chung Heekyung, Kim Doris, Li Hailun, Jandial Danielle, Simpkins Fiona, Abstract B013: Cyclin E1 Positive Protein Status is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer: Part 2 of the DENALI Study (GOG-3066)
  24:10_Supplement, p. B013 - B013 2025
• Annals of oncology
  Kristeleit R S, Pisano C, Buscema J, Demirkiran F, Ueland F, Chudecka-Głaz A, Yeku O, Kim Y B, Fuentes Pradera J, Oaknin A, Prendergast E, Provencher D, Zagouri F, Martin L P, Chou H-H, Beiner M, Anderson C, Drochytek V, Eskander R N, Littell R D, Gao B, Valabrega G, O'Malley D M, Agarwal R, Maloney L, Despain D, Connor C, Craib M, Shih D, Fujiwara K, Monk B J, Ghamande S, Lisyanskaya A, Dean A, Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study 2025
• Journal of clinical oncology
  Banerjee Susana N, Van Nieuwenhuysen Els, Aghajanian Carol, D'Hondt Véronique, Monk Bradley J, Clamp Andrew, Prendergast Emily, Oaknin Ana, Ring Kari, Colombo Nicoletta, Holloway Robert W, Rodrigues Manuel, Chon Hye Sook, Gourley Charlie, Santin Alessandro D, Thaker Premal H, Gennigens Christine, Newman Gregg, Salinas Erin, Youssoufian Hagop, Moore Kathleen N, Lustgarten Stephanie, O'Malley David M, Van Gorp Toon, Grisham Rachel N, Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201, p. JCO2502377 2025
• Obstetrical & gynecological survey
  Olawaiye Alexander B., Vergote Ignace, Kesner-Hays Amanda, Pashova Hristina I., Pai Sachin G., Tudor Iulia Cristina, Jubb Adrian M., Lorusso Domenica, O'Malley David M., Kim Jae-Weon, Garbaos Gabriel, Salutari Vanda, Caruso Giuseppe, Nicum Shibani, Bagameri Andrea, Artioli Grazia, Bodnar Lubomir, Kim Byoung-Gie, Colombo Nicoletta, McClung Emily, Kaczmarek Emilie, Slomovitz Brian, De La Creva Helena, do Carvalho Calabrich Aknar Freire, Cassani Chiara, You Benoit, Churruca Cristina, Gilbert Lucy, Mileshkin Linda, Devaux Alix, Hopp Elizabeth, Lee Yong Jae, Oaknin Ana, Scaranti Mariana, McCollum Michael E., Diakos Connie, Clamp Andrew, Leiser Aliza L., Balazs Boglárka, Monk Bradley J., Scandurra Giuseppa, Van Gorp Toon, Kang Sokbom, Gladieff Laurence, Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial
  80:10, p. 636 - 638 2025
• Annals of oncology
  Ryu S Y, Gil K M, Small, Jr W, Rodgers W, Leath, 3rd C A, Monk B J, Deng W, Albuquerque K, Koh W-J, Mayadev J, Heugel A, Fabian D, Chase D M, Miller K, Kim J-W, Kim B-J, Kim D-Y, Cho C-H, No J H, Mannel R S, Randomized Phase III Trial of Adjuvant Radiation versus Chemoradiation in Intermediate-Risk, Early-stage Cervical Cancer following Radical Hysterectomy and Lymphadenectomy: Results from NRG Oncology/GOG-263/KGOG1008 2025
• Konstantinopoulos Panagiotis A, Kim Jae Weon, Freyer Gilles, Lee Jung Yun, Gaba Lydia, Grisham Rachel N, Colombo Nicoletta, Wu Xiaohua, Sehouli Jalid, Cruz Felipe, Cibula David, Monk Bradley J, Nyvang Gitte Bettina, Friedlander Michael, Lorusso Domenica, Van Nieuwenhuysen Els, Malik Rozita, Glasspool Rosalind, Marth Christian, Leary Alexandra, Cortés-Salgado Alfonso, Zamagni Claudio, Marmé Frederik, Sufliarsky Jozef, Zuradelli Monica, Wang Craig, Hinson Patsy, Su Fei, Paule Ines, Miller Michelle, Matulonis Ursula A, González-Martín Antonio, Primary Analysis of EPIK-O/ENGOT-ov61:Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation 2025
• Gynecologic oncology
  Levin Gabriel, Monk Bradley, Pothuri Bhavana, Coleman Robert, Herzog Thomas, Slomovitz Brian, Racial and ethnic enrollment disparities in clinical trials leading to drug approvals for gynecologic malignancies by the Food and Drug Administration
  200, p. 150 2025
• Gynecologic oncology
  Lee Elizabeth, Call Justin, Winer Ira, Yeku Oladapo, Richardson Debra, Seamon Leigh, Hamilton Erika, Cloven Noelle, Zhang Jian, Kavalerchik Edward, Monk Bradley, Part C of a phase I/II study evaluating single agent rinatabart sesutecan in patients with advanced and/or metastatic platinum-resistant ovarian cancer
  200, p. 112 - 113 2025
• Gynecologic oncology
  File Brittany, Herzog Thomas, Coleman Robert, Tewari Krishnansu, Kapp Daniel, Monk Bradley, Francoeur Alex, Tran Nathan, Richardson Michael, Chan John, Trends in FDA approval of novel therapies in women's cancer: A study of the last 25 years
  200, p. 114 - 115 2025
• Gynecologic oncology
  Salani Ritu, Lindemann Kristina, Zhongqiu L.I.N., Nishio Shin, Oaknin Ana, Kurtz J. Emmanuel, Valabrega Giorgio, Canova Stefania, Cáceres M. Valeria, Harter Philipp, Gilbert Lucy, Sadozye Azmat, Lee Jung-Yun, Van Gorp Toon, Boere Ingrid, Marth Christian, Madry Radoslaw, Zagouri Flora, do Rêgo Barros Lilian Arruda, Duska Linda, Monk Bradley, Li Xin Tong, Bogusz Agata, Toker Sarper, Mirza Mansoor, TroFuse-020/GOG-3101/ENGOT-cx20: A phase III, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy versus treatment of physician's choice as second-line treatment for recurrent or metastatic cervical c
  200, p. 121 - 122 2025
• Gynecologic oncology
  Richardson Michael, Kapp Daniel, Chan John, Coleman Robert, Herzog Thomas, Monk Bradley, Gynecologic cancers in tumor-agnostic trials: Keys to regulatory approval
  200, p. 74 2025
• Gynecologic oncology
  Bujnak Alyssa, Hamilton Alina, Hari Anjali, Hoadley Katherine, Lankes Heather, Monk Bradley, Birrer Michael, Sill Michael, Szot Christopher, Wei Lei, Tewari Krishnansu, Ramirez Nilsa, Huang Helen, Liu Hongwei, Penson Richard, Ramondetta Lois, Landrum Lisa, Oaknin Ana, Reid Thomas, Leitao Mario, Michael Helen, Copeland Larry, Jones Corbin, Reeves Catherine, Predictive biomarkers for chemotherapy plus bevacizumab in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 National Institutes of Health Cancer Moonshot
  200, p. 352 - 353 2025
• Gynecologic oncology
  Lee Jung-Yun, Oaknin Ana, Lorusso Domenica, Kim Kidong, Gilbert Lucy, Lee Yeh Chen, Gao Bo, Tan David, Oza Amit, Miller Rowan, O'Malley David, Monk Bradley, Pothuri Bhavana, Lu Lin, Berman Craig, Borgman Anne, Naumann Wendel, Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: Results from the dose-optimization stage of the REFRαME-O1 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase II/III study
  200, p. 351 2025
• Annals of oncology
  Mercieca-Bebber R., Buck M., Brooks S., Lea J., Stuckey A., Lad T.E., Holschneider C., Spirtos N., Boyd L., Fyles A., Monk B., Stockler M., King M.T., Mileshkin L., Barnes E., Moore K., Diamante K., Lee Y.C., Narayan K., Khaw P., 1172P The relationship between patient-reported outcomes and clinician-rated toxicity in participants with locally advanced cervix cancer in the OUTBACK trial
  36, p. S772 - S773 2025
• Annals of oncology
  Lorusso D., Monk B.J., Park J-Y., Colombo N., Muller C.Y., Kim J-W., Gladieff L., Olawaiye A., Van Gorp T., Bertrán A. Santaballa, Felberbaum R., Bodnar L., Madrid L. Fariñas, Thaker P.H., Pashova H.I., Yadav B.K., Pai S., Mallen A., 1239eTiP BELLA: A phase II study of relacorilant plus nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer
  36, p. S748 - S748 2025
• Annals of oncology
  Monk B.J., Van Nieuwenhuysen E., Tromp J., Lorusso D., O'Cearbhaill R.E., Banerjee S., Collins D.C., Zikan M., Jackson A.L., Madsen K., Gennigens C., Ottevanger P.B., Ghamande S., Salutari V., Baurain J-F., Reyners A., Conte U., Windfeld K., Hansen H., Vergote I., 1166P Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/GOG-3024/ENGOT-cx8 study
  36, p. S769 - S770 2025
• Gynecologic oncology
  Chase Dana, Small William, Huang Helen, Deng Wei, Rodgers William, Mayadev Jyoti, Leath Charles, Monk Bradley, Kim Beob-Jong, Albuquerque Kevin, Kim Dae-Yeon, Cho Chi-Heum, Gil Karen, Ryu Sang Young, Kim Jae-Weon, No Jae Hong, Holman Laura, Stuckey Ashley, Fabian Denise, Smick Alexandra, Wenzel Lari, Patient-reported outcomes on a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate-risk, stage I/IIA cervical cancer treated with initial radical hysterectomy and pelvic lymphadenectomy (NCT#01101451)
  200, p. 4 - 5 2025
• Gynecologic oncology
  Simpkins Fiona, Leary Alexandra, Willmott Lyndsay, Monk Bradley, Frenel Jean-Sebastien, Goh Jeffrey, Slomovitz Brian, Lim Peter, Shannon Catherine, Neff Robert, Kim Doris, Li Hailun, Jandial Danielle, Backes Floor, Starks David, Okera Meena, Secord Angeles Alvarez, O'Malley David, Martin Lainie, Ouali Kaissa, Oehler Martin, Cyclin E1 as a predictive biomarker of azenosertib benefit in platinum-resistant ovarian cancer: Outcomes from part 1b of the DENALI study (GOG-3066)
  200, p. 8 - 9 2025
• Gynecologic oncology
  Ryu Sang Young, Deng Wei, Albuquerque Kevin, Koh Wui-Jin, Mayadev Jyoti, Heugel Anne, Kim Beob-Jong, Kim Dae-Yeon, Cho Chi-Heum, Kim Jae-Weon, No Jae Hong, Mannel Robert, Miller Katherine, Fabian Denise, Small William, Rodgers William, Leath Charles, Monk Bradley, Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical carcinoma following radical hysterectomy and lymphadenectomy: Results of NRG oncology/GOG-263
  200, p. 4 2025
• Gynecologic oncology
  Grisham Rachel, Van Nieuwenhuysen Els, Aghajanian Carol, Monk Bradley, Clamp Andrew, D’hondt Veronique, Prendergast Emily, Oaknin Ana, Ring Kari, Derio Silvia, Holloway Robert, Rodrigues Manuel, Gourley Charlie, Santin Alessandro, Thaker Premal, Chon Hye Sook, Gennigens Christine, Newman Gregg, Moore Kathleen, Lustgarten Stephanie, O'Malley David, Salinas Erin, Youssoufian Hagop, Van Gorp Toon, Banerjee Susana, ENCORE: Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer (ENGOT-OV60/GOG-3052/RAMP 201): Dose intensity and subgroup analysis
  200, p. 34 - 35 2025
• Cancer treatment and research communications
  Monk Bradley J., Patel Manish R., Toker Sarper, Subbiah Vivek, Gordan Lucio N., DEVELOPMENT OF ANTI-CANCER MEDICINES IN THE CURRENT ERA, p. 101002 - 101002 2025
• International journal of gynecological cancer
  Podder Vivek, Coleman Robert L., Eskander Ramez, Flint Michelle, Monk Bradley J., Slomovitz Brian M., Checkpoint Inhibitor Rechallenge in Advanced Endometrial Cancer: Revisiting the Immune Landscape Beyond First-Line Therapy, p. 102124 2025
• Journal of clinical oncology
  Konstantinopoulos Panagiotis A, Hinson Patsy, Zuradelli Monica, Wang Craig, Su Fei, Paule Ines, Miller Michelle, Matulonis Ursula A, González-Martín Antonio, Kim Jae Weon, Freyer Gilles, Lee Jung Yun, Gaba Lydia, Grisham Rachel N, Colombo Nicoletta, Wu Xiaohua, Sehouli Jalid, Cruz Felipe, Cibula David, Monk Bradley J, Nyvang Gitte-Bettina, Friedlander Michael, Lorusso Domenica, Van Nieuwenhuysen Els, Malik Rozita, Glasspool Rosalind, Marth Christian, Leary Alexandra, Cortés-Salgado Alfonso, Zamagni Claudio, Marmé Frederik, Sufliarsky Jozef, Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation, p. JCO2500225 2025
• Journal of clinical oncology
  Banerjee Susana N, Van Nieuwenhuysen Els, Aghajanian Carol, D'Hondt Véronique, Monk Bradley J, Oaknin Ana, Ring Kari, Clamp Andrew, Prendergast Emily, Colombo Nicoletta, Holloway Robert W, Rodrigues Manuel, Chon Hye Sook, Gourley Charlie, Santin Alessandro D, Thaker Premal H, Gennigens Christine, Newman Gregg, Salinas Erin, Youssoufian Hagop, Moore Kathleen N, Lustgarten Stephanie, O'Malley David M, Van Gorp Toon, Grisham Rachel N, , Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201, p. JCO2500112 2025
• Gynecologic oncology
  Chan John K., Tewari Krishnansu, Monk Bradley J., Herzog Thomas J., Coleman Robert L., McHale Michael T., Salani Ritu, Francoeur Alex A., Kapp Daniel S., Richardson Michael T., Optimizing therapy for cervical cancers – Translating trial data into clinical decision-making
  199, p. 47 - 50 2025
• Annals of oncology
  Mayadev J, Kahán Z, Galaz P, Meléndez Mier G, Rey F, Wu X, Estevez-Diz M D P, Limaye S, Xin W, Mandai M, Shapira-Frommer R, Dry H, Broggi M A S, Yuan D Y, Stewart R A, Monk B J, Ramírez Godinez F J, Leiva M, Cetina-Pérez L D C, Varga S, Alarcon-Rozas A E, Valdiviezo N, Acevedo C, Molina Alavez A, Figueroa A, Santini A, Vera L, Vázquez Limón J C, Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses 2025
• The Lancet (British edition)
  Olawaiye Alexander B, Gladieff Laurence, O'Malley David M, Kim Jae-Weon, Garbaos Gabriel, Salutari Vanda, Caruso Giuseppe, Nicum Shibani, Bagaméri Andrea, Artioli Grazia, Bodnar Lubomir, Kang Sokbom, Vergote Ignace, Kesner-Hays Amanda, Pashova Hristina I, Pai Sachin G, Tudor Iulia Cristina, Jubb Adrian M, Gilbert Lucy, Mileshkin Linda, Devaux Alix, Hopp Elizabeth, Lorusso Domenica, Lee Yong Jae, Oaknin Ana, Scaranti Mariana, Kim Byoung-Gie, Colombo Nicoletta, McCollum Michael E, Diakos Connie, Clamp Andrew, Leiser Aliza L, Balázs Boglárka, Monk Bradley J, Scandurra Giuseppa, McClung Emily, Kaczmarek Emilie, Slomovitz Brian, De La Cueva Helena, de Carvalho Calabrich Aknar Freire, Cassani Chiara, You Benoit, Van Gorp Toon, Churruca Cristina, Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial 2025
• International journal of gynecological cancer
  Lightfoot Michelle DS, Rubinstein Maria M., Monk Bradley J., Eskander Ramez N., Lutz Kathleen, Moore Kathleen N., Herzog Thomas J., Pothuri Bhavana, Oral Mucositis Associated with Antibody-Drug Conjugates in Gynecologic Oncology: Strategies for Prevention and Treatment, p. 101997 2025
• Journal of clinical oncology
  Bujnak Alyssa, Hamilton Alina, Sill Michael, Monk Bradley J., Birrer Michael J., Hari Anjali, Lankes Heather A., Hoadley Katherine A., Liu Hongwei, Penson Richard T., Ramondetta Lois M., Oaknin Ana, Leitao Mario Mendes, Copeland Larry J., Ramirez Nilsa C., Szot Christopher, Wei Lei, Tewari Krishnansu Sujata, miRNA(s) expression as predictive biomarkers in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot
  43:16_suppl, p. 5523 - 5523 2025
• International journal of gynecological cancer
  Secord Angeles Alvarez, Alvarez Ronald D., Randall Leslie M., Mannel Robert S., Mutch David, Small Michelle N., Coleman Robert L., Monk Bradley J., Moore Kathleen N., Copeland Larry J., Herzog Thomas J., Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: The GOG Foundation, Inc.’s Scholar Career Development Award and New Investigator Program, p. 101982 2025
• Journal of clinical oncology
  Shahin Mark S., Hietanen Sakari, O’Cearbhaill Roisin E., Mangili Giorgia, Moore Richard G., Berton Dominique, Burger Robert Allen, Braicu Elena Ioana, Monk Bradley J., Rubio-Pérez Maria Jesús, Cloven Noelle, Aaquist Haslund Charlotte, Herzog Thomas J, Shtessel Luda, Lim Jonathan, Gonzalez Martin Antonio, Barretina-Ginesta Maria-Pilar, O’Malley David M., Honhon Brigitte, McCormick Colleen C., Impact of disease progression on health-related quality of life (HRQOL): Updated results from the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line (1L) maintenance therapy in patients with newly diagnosed advanced ovarian cancer (aOC)
  43:16_suppl, p. 5551 - 5551 2025
• Journal of clinical oncology
  Mayadev Jyoti, Vázquez Limón Juan Carlos, RamIrez Godinez Francisco Javier, Leiva Manuel, Cetina Lucely Del Carmen, Varga Szilvia, Molina Alavez Alejandro, Alarcon-Rozas Ashley Efrain, Valdivieso Natalia, Wu Xiaohua, Mandai Masaki, Shapira-Frommer Ronnie, Estevez-Diz Maria Del Pilar, Limaye Sewanti Atul, Xin Wenjing, Broggi Maria, Stewart Ross, Monk Bradley J., Yuan Daniel Y., Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses
  43:16_suppl, p. 5502 - 5502 2025
• Journal of clinical oncology
  Salani Ritu, Lindemann Kristina, Mirza Mansoor Raza, Lin Zhongqiu, Nishio Shin, Oaknin Ana, Kurtz Jean Emmanuel, Valabrega Giorgio, Cáceres Valeria, Harter Philipp, Gilbert Lucy, Sadozye Azmat, De Rêgo Barros Lilian Arruda, Van Gorp Toon, Boere Ingrid A., Marth Christian, Duska Linda R., Monk Bradley J., Li Xin Tong, Tekin Cumhur, , TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of physician’s choice as second-line treatment for recurrent or metastatic cervical cancer
  43:16_suppl 2025
• Journal of clinical oncology
  Mercieca-Bebber Rebecca, Barnes Elizabeth H., Moore Kathleen N., Lee Yeh Chen, Narayan Kailash, Khaw Pearly, Buck Martin, Fyles Anthony, Brooks Susan, Lea Jayanthi Sivasothy, Stuckey Ashley, Lad Thomas E., Holschneider Christine, Spirtos Nicola M., Boyd Leslie R., Small William, Monk Bradley J., Stockler Martin R., King Madeleine T., Mileshkin Linda R., Patient-reported outcomes (PROs) in locally advanced cervical cancer (LACC): Insights from the OUTBACK trial
  43:16_suppl, p. 5503 - 5503 2025
• ESMO open
  Oaknin A., Fujiwara K., Kristeleit R., Monk B.J., Prendergast E., Salutari V., Littell R., Schenker M., Martinez-Garcia J., Ueland F., Lee J-Y., De Vivo R., Yeku O., Dean A., Bese T., Jewell A., Van Gorp T., Diaz J., Maloney L., 75MO Efficacy and safety of rucaparib maintenance treatment in patients from ATHENA-MONO/GOG-3020/ENGOT-ov45 with newly diagnosed advanced ovarian cancer not associated with homologous recombination deficiency
  10 2025
• ESMO open
  Okines A., Curigliano G., Mizuno N., Oh D-Y., Rorive A., Soliman H., Takahashi S., Bekaii-Saab T., Hamilton E.P., Monk B.J., Nakamura Y., Nguyen D., O'Malley D., Reck M., Yu E., Drees A., Ramos J.D., Tan Q., Stinchcombe T., Pohlmann P.R., 304MO Tucatinib and trastuzumab for previously treated HER2-mut MBC: Final analysis of a phase II basket study (SGNTUC-019)
  10, p. 104876 2025
• International journal of gynecological cancer
  Podder Vivek, Grisham Rachel N., Coleman Robert L., Cobb Lauren Patterson, Monk Bradley J., Herzog Thomas, Gershenson David M., Slomovitz Brian M., Repurposing FDA-Approved Cancer Therapies: Exploring Endocrine and Targeted Pathways in Low-Grade Serous Ovarian Cancer Treatment, p. 101938 2025
• Cancer treatment reviews
  Monk Bradley J., Lorusso Domenica, Fujiwara Keiichi, Sehouli Jalid, Optimal bevacizumab treatment strategy in advanced ovarian cancer: A review, p. 102945 2025
• Gynecologic oncology
  Matulonis Ursula A., Berton Dominique, Berek Jonathan S., Redondo Andrés, Herrstedt Jørn, Oza Amit, Mahner Sven, Haslund Charlotte A., Marmé Frederik, Tinker Anna V., Ledermann Jonathan A., Benigno Benedict, Lindahl Gabriel, Mirza Mansoor R., González-Martín Antonio, Bécourt Stéphanie, Colombo Nicoletta, Malinowska Izabela A., Liu Wenlei, Bains Manjinder, Monk Bradley J., ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety
  195, p. 192 2025
• Gynecologic oncology
  Leath, 3rd Charles A, Deng Wei, Mell Loren K, Richardson Debra L, Walker Joan L, Holman Laura L, Lea Jayanthi S, Amarnath Sudha R, Santos-Reyes Luis Javier, Arend Rebecca C, Mayadev Jyoti, Jegadeesh Naresh, DiSilvestro Paul, Chon Hye Sook, Ghamande Sharad A, Gao Lei, Albuquerque Kevin, Chino Junzo P, Donnelly Eric, Feddock Jonathan M, Lowenstein Jessica, Quick Allison M, Kunos Charles M, MacKay Helen, Aghajanian Carol, Monk Bradley J, Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial
  195, p. 122 - 133 2025
• Gynecologic oncology
  Carter Jeanne, Huang Helen Q, Monk Bradley J, Kim Yong-Beom, Kim Moon-Hong, Stuckey Ashley, Vicus Danielle L, Holman Laura L, Fleury Aimee C, Pearson J Matthew, Thawani Nitika, Shahin Mark, Lea Jayanthi, Robertson Sharon E, Warshal David, Backes Floor J, Feltmate Colleen, Wilkinson-Ryan Ivy, Covens Allan, Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278)
  195, p. 50 2025
• Gynecologic oncology
  Covens Allan, DiSilvestro Paul, Monk Bradley J, Kim Yong-Beom, Kim Moon-Hong, Huang Helen Q, Fleury Almee, Pearson J Matthew, Thawani Nitika, Vicus Danielle, Holman Laura L, Shahin Mark S, Lea Jayanthi S, Robertson Sharon E, Feltmate Colleen, Dewdney Summer, Leitao Mario M, Wilkinson-Ryan Ivy, Warshal David, Backes Floor, Elsayed Ahmed G, Carter Jeanne, Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278)
  195, p. 59 2025
• International journal of gynecological cancer
  Leitao Mario M., Randall Leslie M., Bixel Kristin L., Chase Dana Meredith, Quick Allison, McCormick Colleen, Black Destin, Lim Peter C., Eskander Ramez N., Walker Joan L., Copeland Larry J., Monk Bradley J., Gotlieb Walter H., LoCoco Salvatore, Martino Martin A., ROCC/GOG-3043: A randomized controlled trial of robotic versus open surgery for early-stage cervical cancer, p. 101760 2025
• International journal of gynecological cancer
  Salani Ritu, Lindemann Kristina, Lin Zhongqiu, Nishio Shin, Oaknin Ana, Kurtz Jean-Emmanuel, Valabrega Giorgio, Cáceres M. Valeria, Harter Philipp, Gilbert Lucy, Sadozye Azmat H., Do Rêgo Barros Lilian Arruda, Van Gorp Toon, Boere Ingrid, Marth Christian, Monk Bradley J., Li Xin Tong, Tekin Cumhur, Mirza Mansoor Raza, Duska Linda, TroFuse-020/GOG-3101/ENGOT-Cx20: A Phase 3, Randomised, Active-Controlled, Open-Label, Multicentre Study Comparing Sacituzumab Tirumotecan Monotherapy Vs Treatment Of Physician’s Choice As Second-Line Treatment For Recurrent Or Metastatic Cervical Cancer
  35:2, p. 100497 2025
• International journal of gynecological cancer
  Ghamande Sharad, Miller Rowan E., Solovyeva Ekaterina, Prendergast Emily, Del Mar Gordon Santiago Maria, Kim Yong-Man, Littell Ramey, Anttila Maarit, Connor Christy, Craib Marcia, Fujiwara Keiichi, Monk Bradley J., Kristeleit Rebecca S., Ruiz Nuria, Bessette Paul, Van Le Linda, Turna Hande, Westin Shannon N., Zvaríková Mária, Eskander Ramez N., ATHENA-MONO Post-Progression Survival Data Update In Patients With Newly Diagnosed Advanced Ovarian Cancer
  35:2, p. 100319 2025
• International journal of gynecological cancer
  Lokich Elizabeth, Jørgensen Trine Lembrecht, Black Destin, Cibula David, Gilbert Lucy, Savarese Antonella, Powell Matthew A., Herbertson Rebecca, Gill Sarah E., Monk Bradley J., Nevadunsky Nicole, Cloven Noelle, Podzielinski Iwona, Myers Tashanna, Dabrowski Christine, Ring Kari L., Stevens Shadi, Willmott Lyndsay, Mirza Mansoor Raza, Time Course Of Adverse Events In Primary Advanced Or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy In The ENGOT-EN-6-NSGO/GOG-3031/RUBY Trial
  35:2, p. 101722 2025
• European journal of cancer (1990)
  Vergote Ignace, Van Gorp Toon, Laenen Annouschka, Scambia Giovanni, Thaker Premal H., Cibula David, Colombo Nicoletta, Lea Jayanthi, Gonzalez-Martin Antonio, Korach Jacob, Sehouli Jalid, Monk Bradley J., Heinzelmann-Schwarz Viola, Berger Regina, Lau Susie, Mądry Radoslaw, Denys Hannelore, Buscema Joseph, Pepin Jessica Thomes, Salutari Vanda, Bagaméri Andrea, Ardizzoia Antonio, Copeland Larry J., Henry Stéphanie, Cecere Sabrina Chiara, Hruda Martin, Iglesias David A., Manso Luis, Shai Ayelet, O’Malley David M., Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study, p. 115306 2025
• International journal of gynecological cancer
  Lorusso Domenica, Monk Bradley J., Barretina-Ginesta Maria-Pilar, Pothuri Bhavana, Vergote Ignace, O’malley David M., Haslund Charlotte A., O’cearbhaill Roisin E., Abadie-Lacourtoisie Sophie, Backes Floor J., Heitz Florian, Chase Dana M., Amit Amnon, Moore Kathleen N., Graybill Whitney S., Herzog Thomas J., Golembesky Amanda K., Malinowska Izabela A., Rubio Pérez Maria-Jesús, González-Martín Antonio, Updated Patient-Reported Outcomes In The PRIMA/ENGOT-OV26/GOG-3012 Trial Of Niraparib First-Line Maintenance Therapy In Patients With Newly Diagnosed Advanced Ovarian Cancer
  35:2, p. 100093 2025
• Therapeutic advances in medical oncology
  Powell Matthew A, Novák Zoltán, Black Destin, Gilbert Lucy, Sharma Sudarshan, Stuckey Ashley, Boere Ingrid, Gold Michael A, Segev Yakir, Pothuri Bhavana, Monk Bradley J, Shahin Mark S, Grimshaw Matthew, Stevens Shadi, Lai Dominic W, McCourt Carolyn, Mirza Mansoor Raza, Buscema Joseph, Coleman Robert L, Gennigens Christine, Sebastianelli Alexandra, Gill Sarah E, Valabrega Giorgio, Landrum Lisa M, Gropp-Meier Martina, Slomovitz Brian M, Ring Kari L, Herzog Thomas J, Balas Morad Marco, Bjørge Line, Willmott Lyndsay, A plain language summary publication of patients' survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel
  17, p. 17588359251342241 2025
• Journal of gynecologic oncology
  Kim Yong-Man, Hasegawa Kosei, Dubot Coraline, Cáceres M. Valeria, Tewari Krishnansu S., Lorusso Domenica, Lee Jeong-Won, Liou Wen-Shiung, Li Kan, Nishio Shin, Kim Se Ik, Tekin Cumhur, Colombo Nicoletta, Monk Bradley J., Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
  36 2025
• Annals of oncology
  González-Martín A, Malinowska I A, Monk B J, Reply to Letter to the Editor 'Long-term outcomes in the PRIMA trial: a closer look at PFS and OS' by Wu et al 2024
• Annals of oncology
  Lorusso D, Colombo N, Dubot C, Cáceres M V, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera M, Castonguay V, Arkhipov A, Li K, Toker S, Samouëlian V, Tekin C, Tewari K S, Monk B J, Pembrolizumab Plus Chemotherapy for Advanced and Recurrent Cervical Cancer: Final Analysis According to Bevacizumab Use in the Randomized KEYNOTE-826 Study 2024
• International journal of gynecological cancer
  Barlin Joyce, Black Destin, Cottrill Hope, Hand Lauren, Eshed Helen, O’Malley David, Chuang Linus, Chisamore Michael, Durbin Joan, Zheng Pan, Liu Yang, Shpyro Svetlana, Monk Bradley, Lim Peter, Pepin Jessica Thomes, Hopp Elizabeth, Cloven Noelle, LB010/#1590  A phase 2 randomized dose optimization trial of gotistobart, a PH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer (PROC, preserve-004/GOG-3081; NCT05446298)
  34, p. A6 - A8 2024
• International journal of gynecological cancer
  Lorusso Domenica, Van Gorp Toon, Zagouri Flora, Bodnar Lubomir, Collins Dearbhaile, Korach Jacob, Marth Christian, Kroep Judith, Zhu Jianqing, Hasegawa Kosei, Samouëlian Vanessa, Lee Jung-Yun, Casarotto Fernanda, Antill Yoland, Chase Dana, Shahin Mark, Orlowski Robert, Woodhouse Kristina, Cui Yi, Willmott Lyndsay, Monk Bradley, TP003/#1538  Phase 3 ENGOT-en23/GOG-3095/MK-2870–005 study: sacituzumab tirumotecan (Sac-TMT) monotherapy vs treatment of physician’s choice chemotherapy in patients with endometrial cancer who received prior chemotherapy and immunotherapy
  34, p. A348 - A348 2024
• International journal of gynecological cancer
  Grisham Rachel, Monk Bradley, Van Nieuwenhuysen Els, Moore Kathleen, Fabbro Michel, O’Malley David, Oaknin Ana, Thaker Premal, Oza Amit, Colombo Nicoletta, Lustgarten Stephanie, Youssoufian Hagop, Banerjee Susana, PR029/#943  A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of therapy in patients with recurrent low-grade serous ovarian cancer: GOG-3097/ENGOT-ov81/NCRI/RAMP 301
  34, p. A53 - A54 2024
• International journal of gynecological cancer
  Bixel Kristin, Baiocchi Glauco, Black Destin, Eskander Ramez, Gotlieb Walter, Lee Sun Joo, Lococo Salvatore, Martino Martin, Mccormick Colleen, Monk Bradley, Quick Allison, Walker Joan, Randall Leslie, Leitao Mario, Chase Dana, TP001/#1584  GOG-3043 (nct04831580): a randomized non-inferiority trial of robotic versus open surgery for early stage cervical cancer (ROCC)
  34, p. A347 - A347 2024
• International journal of gynecological cancer
  Oaknin Ana, Lee Jung-Yun, Lorusso Domenica, Pietzner Klaus, Cibula David, Lee Yeh Chen, Schilder Russell, Auranen Annika, Gao Bo, Tan David, Oza Amit, Miller Rowan, Salutari Vanda, Tasca Giulia, O’Malley David, Monk Bradley, Pothuri Bhavana, Lu Lin, Berman Craig, Borgman Anne, Wendel Naumann R., TP010/#1537  Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: the reframe-01 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase 2/3 study
  34, p. A351 - A351 2024
• International journal of gynecological cancer
  Banerjee Susana, Kalbacher Elsa, Van Gorp Toon, Lustgarten Stephanie, Youssoufian Hagop, Grisham Rachel, Aghajanian Carol, Santin Alessandro, Ring Kari, Colombo Nicoletta, Van Nieuwenhuysen Els, Thaker Premal, Prendergast Emily, Moore Kathleen, Chon Hye Sook, Clamp Andrew, O’malley David, Monk Bradley, Cortés-Salgado Alfonso, Fabbro Michel, LB007/#1548  Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201
  34, p. A13 - A13 2024
• International journal of gynecological cancer
  Vergote Ignace, Colombo Nicoletta, Valabrega Giorgio, Monk Bradley J, Herzog Thomas, Perez Fidalgo Alejandro, Cibula David, Pothuri Bhavana, Sehouli Jalid, Korach Jacob, Barlin Joyce, Papadimitriou Christos A, van Gorp Toon, Richardson Debra, McCarthy Michael, Antill Yoland, Mirza Mansoor Raza, Li Kai, Kalyanapu Pratheek, Slomovitz Brian, Coleman Robert L, ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: ratio
  34:8, p. 1283 2024
• Chan John, Tian Chunqiao, Monk Bradley, McNally Leah, Kesterson Joshua, Lin Ken, Darcy Kathleen, Richardson Michael, Kapp Daniel, Landrum Lisa, Copeland Larry, Berry Laurel, Bell Jeffery, Walker Joan, Wenham Robert, Phippen Neil, Spirtos Nick, Tewari Krishnansu, Shahin Mark, Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study 2024
• Gynecologic oncology
  Valabrega Giorgio, Pothuri Bhavana, Oaknin Ana, Graybill Whitney S, Sánchez Ana Beatriz, McCormick Colleen, Baurain Jean-François, Tinker Anna V, Denys Hannelore, O'Cearbhaill Roisin E, Hietanen Sakari, Moore Richard G, Knudsen Anja Ør, de La Motte Rouge Thibault, Heitz Florian, Levy Tally, York Whitney, Gupta Divya, Monk Bradley J, González-Martín Antonio, Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial 2024
• Gynecologic oncology
  Randall Leslie M., O'Malley David M., Gaillard Stephanie, Monk Bradley J., Coleman Robert L., Adams Sarah, Duska Linda R., Dalton Heather, Holloway Robert W., Huang Marilyn, , Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032)
  178, p. 161 - 169 2023
• Journal of clinical oncology
  Gourley Charlie, Dalton Heather J., Banerjee Susana N., Buscema Joseph, Monk Bradley J., Lockley Michelle, Krell Jonathan, PRO-105, a phase II open-label study of NUC-1031 in patients with platinum-resistant ovarian cancer
  36:15_suppl, p. TPS5612 - TPS5612 2018